Do Peptides Work? Ask The Doc

An app member asks whether peptides actually work, after being sold several products at a longevity clinic. The speaker says he has used TRT for about two years and previously tried growth hormone personally. Because real growth hormone was expensive at the time, cheaper secretagogues are mentioned as a replacement trend. The response frames peptide marketing as a space where bold promises often exceed published human data. Rather than mocking users, the tone encourages critical thinking about what benefits are truly measurable. IGF and growth hormone effects are described as real in principle, yet not automatically safe for everyone. The practical point is that spending money does not guarantee outcomes, especially with unproven mixtures.

Cancer risk is raised repeatedly, with examples like skin, colon, pancreatic, brain, and prostate cancer. The transcript says older men already face rising baseline cancer odds, regardless of supplements or hormones. Heart risks are also mentioned, including heart attacks and later life heart disease complications. In this framing, longevity decisions should weigh benefits against the reality of severe medical endpoints. The speaker notes that studies of very old populations exclude people who already died from cancer earlier. That survival bias is used to caution against simplistic claims about hormones and protective effects. The message is to avoid magical thinking, because biology still has tradeoffs and unpredictable outcomes.

Monitoring is emphasized as the safest approach for anyone choosing additional growth products or peptides. The ABCDS framework is referenced as a structured way to track cardiovascular and overall risk factors. The transcript suggests that doing nothing can be reasonable if goals are vague or evidence is thin. For people who insist on experimenting, careful labs and follow up are advised instead of blind stacking. Specific cancers are mentioned again as worries, alongside leukemia and lymphoma as frightening diagnoses. The response closes by reminding listeners that data gaps remain, so caution should guide decision making. Ultimately the speaker supports informed personal choice, while warning that peptides are not harmless toys.